Used primarily in the treatment of acute myeloid leukemia (AML), especially in patients with FLT3 internal tandem duplication (ITD) mutations. It functions as a selective and potent inhibitor of the FLT3 receptor tyrosine kinase, helping to suppress the growth of leukemic cells. Quizartinib has shown efficacy in reducing tumor burden and prolonging survival in relapsed or refractory AML cases. It is often used in combination with standard chemotherapy or as a bridge to hematopoietic stem cell transplantation. Clinical development focuses on improving outcomes for high-risk AML subgroups with targeted therapy.